Pharma Mar SA (OTCMKTS:PHMMF) shares reached a new 52-week high on Monday . The stock traded as high as $6.93 and last traded at $6.84, with a volume of 6973 shares. The stock had previously closed at $6.35.
Several equities research analysts recently weighed in on PHMMF shares. Zacks Investment Research cut shares of Pharma Mar from a “buy” rating to a “hold” rating in a research report on Friday, April 17th. ValuEngine raised shares of Pharma Mar from a “sell” rating to a “hold” rating in a research report on Tuesday, March 24th.
The stock’s 50 day moving average is $5.66 and its 200 day moving average is $4.28.
Pharma Mar, SA, a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. The company operates through two segments, Biopharmaceuticals and Consumer Chemicals. It develops and commercializes Yondelis, an antitumor agent for the treatment of advanced soft tissue sarcomas and for relapsed ovarian cancer.
Read More: 52 Week Highs
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.